Next Article in Journal
Morniga-G, a T/Tn-Specific Lectin, Induces Leukemic Cell Death via Caspase and DR5 Receptor-Dependent Pathways
Next Article in Special Issue
Glutamine Addiction and Therapeutic Strategies in Lung Cancer
Previous Article in Journal
Relapse of Acute Myeloid Leukemia after Allogeneic Stem Cell Transplantation: Prevention, Detection, and Treatment
Article Menu
Issue 1 (January-1) cover image

Export Article

Open AccessReview
Int. J. Mol. Sci. 2019, 20(1), 229;

Targeting Mitochondria for Treatment of Chemoresistant Ovarian Cancer

Masonic Cancer Center and Department of Obstetrics, Gynecology and Women’s Heath, University of Minnesota, Minneapolis, MN 55455, USA
Department of Obstetrics and Gynecology, University of Virginia, Charlottesville, VA 22908, USA
Cancer Center Karolinska, Department of Oncology and Pathology, Karolinska Institute, S-171 76 Stockholm, Sweden
Department of Medical Health Sciences (IMH), Linköping University, S-751 85 Linköping, Sweden
Authors to whom correspondence should be addressed.
Received: 26 November 2018 / Revised: 20 December 2018 / Accepted: 23 December 2018 / Published: 8 January 2019
Full-Text   |   PDF [1366 KB, uploaded 8 January 2019]   |  
  |   Review Reports


Ovarian cancer is the leading cause of death from gynecologic malignancy in the Western world. This is due, in part, to the fact that despite standard treatment of surgery and platinum/paclitaxel most patients recur with ultimately chemoresistant disease. Ovarian cancer is a unique form of solid tumor that develops, metastasizes and recurs in the same space, the abdominal cavity, which becomes a unique microenvironment characterized by ascites, hypoxia and low glucose levels. It is under these conditions that cancer cells adapt and switch to mitochondrial respiration, which becomes crucial to their survival, and therefore an ideal metabolic target for chemoresistant ovarian cancer. Importantly, independent of microenvironmental factors, mitochondria spatial redistribution has been associated to both tumor metastasis and chemoresistance in ovarian cancer while specific sets of genetic mutations have been shown to cause aberrant dependence on mitochondrial pathways in the most aggressive ovarian cancer subtypes. In this review we summarize on targeting mitochondria for treatment of chemoresistant ovarian cancer and current state of understanding of the role of mitochondria respiration in ovarian cancer. We feel this is an important and timely topic given that ovarian cancer remains the deadliest of the gynecological diseases, and that the mitochondrial pathway has recently emerged as critical in sustaining solid tumor progression. View Full-Text
Keywords: ascites; OXPHOS; mitochondrial inhibitor; chemoresistant ovarian cancer; SWI/SNF complex ascites; OXPHOS; mitochondrial inhibitor; chemoresistant ovarian cancer; SWI/SNF complex

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Emmings, E.; Mullany, S.; Chang, Z.; Landen, C.N., Jr.; Linder, S.; Bazzaro, M. Targeting Mitochondria for Treatment of Chemoresistant Ovarian Cancer. Int. J. Mol. Sci. 2019, 20, 229.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top